In principle, the hu225 VH and VL fragments used in IgG-scTRAIL have been shown to inhibit, as demonstrated for the Db-scTRAIL format, EGFR tyrosine autophosphorylation in a similar manner like cetuximab13,21, which can potentially result in additional growth inhibitory effects in EGFR/MAPK pathway wild-type tumour cells. The gene discussed is EGFR; the disease is neoplasm.